EJBY, Denmark, April 28, 2025 /PRNewswire/ -- Scantox Group has released their 2024 Annual Report today. It highlights the many activities the company has done over the year to shape the future of a business that in so many ways contribute to improve lives worldwide through the development of new drugs and treatments.
"Our 2024 result shows high profitable growth from transformational acquisitions. We are very pleased with these successful acquisitions and with the integration of Scantox Neuro GmbH and Gentronix Ltd, while delivering organic revenue growth and strong profitability in a challenging market environment," says CFO of Scantox Group, Martin Amtoft-Christensen.
With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support.
"We have in 2024 continued to demonstrate our commitment to expanding both service offerings and geographic reach, serving as a "one-stop-shop" to foster deeper collaboration, whilst remaining steadfast to our core value: being a trusted partner that delivers high-quality, science-led interactions from first contact to final report," Christensen explains.
"Going forward, Scantox will continue to grow our business with both new and existing clients - from virtual biotech companies to the largest global pharma companies - by offering an ever-expanding portfolio of high-quality services. Simultaneously, we are investing in our operations to digitize processes and introduce new models where they benefit our clients."
Scantox is a leading preclinical contract research organization (CRO) accelerating the drug discovery and development process for clients worldwide with a service portfolio covering all main areas within Discovery, Regulatory Toxicology and Analytical Services. The company is headquartered in Denmark, with subsidiaries in Denmark, Sweden, Austria and the UK.
Read the full report: https://scantox.com/about-scantox/annual-report/
Logo: https://mma.prnewswire.com/media/2674623/Scantox_Group_Logo.jpg
Comunicato stampa - Responsabilità editoriale PrNewswire
